[go: up one dir, main page]

NO20031138L - Oftalmiske opplösninger - Google Patents

Oftalmiske opplösninger

Info

Publication number
NO20031138L
NO20031138L NO20031138A NO20031138A NO20031138L NO 20031138 L NO20031138 L NO 20031138L NO 20031138 A NO20031138 A NO 20031138A NO 20031138 A NO20031138 A NO 20031138A NO 20031138 L NO20031138 L NO 20031138L
Authority
NO
Norway
Prior art keywords
prostaglandin derivatives
ophthalmic solutions
water
liable
remarkably inhibited
Prior art date
Application number
NO20031138A
Other languages
English (en)
Other versions
NO20031138D0 (no
NO332650B1 (no
Inventor
Kenji Morishima
Akio Kimura
Hiroyuki Asada
Masayuki Umeda
Mitsuaki Kuwano
Original Assignee
Asahi Glass Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18762864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20031138(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asahi Glass Co Ltd filed Critical Asahi Glass Co Ltd
Publication of NO20031138D0 publication Critical patent/NO20031138D0/no
Publication of NO20031138L publication Critical patent/NO20031138L/no
Publication of NO332650B1 publication Critical patent/NO332650B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
NO20031138A 2000-09-13 2003-03-12 En oftalmisk losning samt fremgangsmater for a forhindre konsentrasjonssenking og inhibere adsorpsjon av et prostaglandinderivat NO332650B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000277554 2000-09-13
PCT/JP2001/007928 WO2002022131A1 (fr) 2000-09-13 2001-09-13 Collyre

Publications (3)

Publication Number Publication Date
NO20031138D0 NO20031138D0 (no) 2003-03-12
NO20031138L true NO20031138L (no) 2003-05-12
NO332650B1 NO332650B1 (no) 2012-11-26

Family

ID=18762864

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031138A NO332650B1 (no) 2000-09-13 2003-03-12 En oftalmisk losning samt fremgangsmater for a forhindre konsentrasjonssenking og inhibere adsorpsjon av et prostaglandinderivat

Country Status (14)

Country Link
US (4) US20040097592A1 (no)
EP (1) EP1321144B1 (no)
KR (1) KR100854056B1 (no)
CN (1) CN1243548C (no)
AT (1) ATE490761T1 (no)
AU (1) AU2001286210A1 (no)
CA (1) CA2422031C (no)
CY (2) CY1113200T1 (no)
DE (1) DE60143615D1 (no)
DK (1) DK1321144T3 (no)
ES (1) ES2357551T3 (no)
NO (1) NO332650B1 (no)
PT (1) PT1321144E (no)
WO (1) WO2002022131A1 (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100854056B1 (ko) * 2000-09-13 2008-08-26 산텐 세이야꾸 가부시키가이샤 점안액
ES2294361T3 (es) * 2002-08-23 2008-04-01 Santen Pharmaceutical Co., Ltd. Colirios estables que contienen latanoprost como principio activo.
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
EP1666043B1 (en) * 2003-07-31 2009-12-02 Santen Pharmaceutical Co., Ltd. Product containing prostaglandin
ES2331313T3 (es) 2003-11-07 2009-12-29 Senju Pharmaceutical Co., Ltd. Composicion farmaceutica que contiene prostaglandina.
CN102526064A (zh) * 2004-12-09 2012-07-04 参天制药株式会社 含有分子内具有氟原子的前列腺素的制品
EP1829545B1 (en) * 2004-12-24 2012-05-02 Santen Pharmaceutical Co., Ltd. Prostaglandin f2 alpha derivative containing products
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
KR101396731B1 (ko) 2005-03-31 2014-05-19 산텐 세이야꾸 가부시키가이샤 프로스타글란딘 Ｆ２ａ 유도체를 유효 성분으로서 함유하는망막신경세포 보호제
RU2392938C2 (ru) 2005-04-13 2010-06-27 Убе Индастриз, Лтд Защитное средство для нейронных клеток сетчатки, содержащее в качестве активного ингредиента производные индазола
CN103768070A (zh) 2006-03-13 2014-05-07 株式会社·R-技术上野 水性组合物
FR2912207B1 (fr) * 2007-02-01 2012-10-26 Air Liquide Procede et appareil de production de monoxyde de carbone par distillation cryogenique
KR101475965B1 (ko) * 2007-03-29 2014-12-23 산텐 세이야꾸 가부시키가이샤 플루오로메토론을 함유하는 현탁형 점안제
EP1985298A1 (en) * 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
US8673937B2 (en) 2008-04-23 2014-03-18 Otsuka Pharmaceutical Co., Ltd. Eye-drop preparation and use thereof
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
WO2010016044A1 (en) * 2008-08-05 2010-02-11 University College Cork, National University Of Ireland, Cork Treatment of retinal degeneration
WO2010100656A2 (en) * 2009-02-20 2010-09-10 Micro Labs Limited Storage stable prostaglandin product
EP2269575A1 (en) 2009-06-30 2011-01-05 Santen Pharmaceutical Co., Ltd Method for improving bioavailability of latanoprost
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
DK2366408T3 (da) * 2010-03-01 2012-10-22 Salvat Lab Sa Vandige, klare opløsninger af fluocinolonacetonid til behandling af inflammation i øret
EP2452669A1 (en) 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
EP2567689A1 (en) * 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
KR102068858B1 (ko) * 2012-06-08 2020-01-21 라이온 가부시키가이샤 점막용 조성물
CN104288092A (zh) * 2013-07-16 2015-01-21 广东东阳光药业有限公司 拉坦前列素滴眼剂
CN104622798B (zh) * 2014-12-05 2017-12-22 广东东阳光药业有限公司 一种含有他氟前列素的滴眼液及其制备方法
WO2018033854A1 (en) 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
EP3590513A4 (en) * 2017-02-28 2020-12-30 Kowa Company, Ltd. DRUG
EP4285908A3 (en) 2017-03-27 2024-02-14 Alcon Inc. Pharmaceutical preparation
EA202190214A1 (ru) 2018-07-09 2021-04-16 Варшавске Закляды Фармацеутычне Польфа Са Офтальмологическое дозирующее устройство
JP2022511335A (ja) * 2018-09-21 2022-01-31 ピー・エス・セラピー・リミテッド 人工涙液組成物、コンタクトレンズ組成物及び薬剤ビヒクル組成物、並びにこれらの使用の方法
CN113038932A (zh) 2018-10-25 2021-06-25 (株)纳斯摩仕 包含Aptamin C作为有效成分的滴眼液组合物
BR112022010871A2 (pt) * 2019-12-05 2022-08-23 Vanda Pharmaceuticals Inc Composições farmacêuticas oftalmológicas
US12357594B1 (en) 2021-06-30 2025-07-15 Sage Products, Llc Antimicrobial solution for pre-operative preparation
CN117180188A (zh) * 2023-08-24 2023-12-08 南京海纳制药有限公司 一种含有他氟前列素滴眼水性药物及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310543A (en) * 1980-10-09 1982-01-12 Hoffmann-La Roche Inc. Prostaglandin compositions
EP0308135B1 (en) * 1987-09-18 1992-11-19 R-Tech Ueno Ltd. Ocular hypotensive agents
JPH0662417B2 (ja) * 1987-12-25 1994-08-17 参天製薬株式会社 抗アレルギー点眼液
US5565492A (en) * 1988-07-18 1996-10-15 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
JPH063800A (ja) * 1992-06-16 1994-01-14 Dainippon Screen Mfg Co Ltd 画像処理方法
AU665287B2 (en) * 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5486540A (en) * 1993-10-28 1996-01-23 Allergan, Inc. Cyclopentane heptanoic or heptenoic acid, 2-arylalkyl or arylalkenyl and derivatives as therapeutic agents
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
ATE221048T1 (de) * 1996-09-17 2002-08-15 Asahi Glass Co Ltd Fluorierte prostaglandinderivate und medikamente
JP3480549B2 (ja) * 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6235781B1 (en) * 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
BR9906597A (pt) * 1998-07-14 2000-07-18 Alcon Lab Inc Produto de prostaglandina
AU2183900A (en) * 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
HK1041655A1 (zh) * 1999-01-19 2002-07-19 法玛西雅厄普约翰美国公司 γ-照射消毒的聚乙烯包装
KR100854056B1 (ko) * 2000-09-13 2008-08-26 산텐 세이야꾸 가부시키가이샤 점안액
TW586946B (en) * 2000-12-22 2004-05-11 Novartis Ag Process to improve stability
EP1666043B1 (en) * 2003-07-31 2009-12-02 Santen Pharmaceutical Co., Ltd. Product containing prostaglandin
US20050049311A1 (en) * 2003-09-03 2005-03-03 Pharmacia & Upjohn Company Medicinal products comprising prostaglandin compositions and methods of packaging such compositions

Also Published As

Publication number Publication date
CY1113200T1 (el) 2014-04-09
CY2011007I1 (el) 2014-04-09
DK1321144T3 (da) 2011-03-07
US20160106757A1 (en) 2016-04-21
CA2422031C (en) 2011-11-15
NO20031138D0 (no) 2003-03-12
CY2011007I2 (el) 2015-08-05
AU2001286210A1 (en) 2002-03-26
ES2357551T3 (es) 2011-04-27
US20070248697A1 (en) 2007-10-25
EP1321144A1 (en) 2003-06-25
CN1457256A (zh) 2003-11-19
US20180353518A1 (en) 2018-12-13
DE60143615D1 (de) 2011-01-20
ATE490761T1 (de) 2010-12-15
NO332650B1 (no) 2012-11-26
PT1321144E (pt) 2011-03-10
EP1321144A4 (en) 2009-07-29
KR20030029981A (ko) 2003-04-16
CN1243548C (zh) 2006-03-01
CA2422031A1 (en) 2003-03-12
KR100854056B1 (ko) 2008-08-26
US20040097592A1 (en) 2004-05-20
WO2002022131A1 (fr) 2002-03-21
EP1321144B1 (en) 2010-12-08

Similar Documents

Publication Publication Date Title
NO20031138D0 (no) Oftalmiske opplösninger
CA2498233A1 (en) Clear ophthalmic solution comprising latanoprost as active ingredient
ES2085490T3 (es) Composiciones de tintas a base de agua.
DK1273299T3 (da) Minoxidilinindeholdende praparater
CA2124873A1 (en) Iodine-containing corrosion inhibitor for oil field acidizing operations
NO960062D0 (no) Farmasöytiske preparater for tungt opplöselige aktive midler
DE60104872D1 (de) Stabilisierte ophthalmische wasserstoffperoxidlösung
DE60007616D1 (de) Kosmetische zusammensetzungen enthaltend vitamin b3
HRP20021011B1 (en) Highly concentrated stable meloxicam solutions
SE0201659D0 (sv) Modified release pharmaceutical formulation
RU2007137960A (ru) СПОСОБ ЛЕЧЕНИЯ АКТИНИЧЕСКОГО КЕРАТОЗА (ВАРИАНТЫ) И 2-МЕТИЛ-1-(2-МЕТИЛПРОПИЛ)-1Н-ИМИДАЗО[4,5-c]]1,5]НАФТИРИДИН-4-АМИН В КАЧЕСТВЕ СРЕДСТВА ЛЕЧЕНИЯ АКТИНИЧЕСКОГО КЕРАТОЗА
BR9406847A (pt) Formulação aquosa estável
DK1301077T3 (da) Antimikrobielt præparat, som er nyttigt til behandling af bovin mastitis
CO5611133A2 (es) Composicion oftalmica que comprende ascomicina
ES2108876T5 (es) Un procedimiento para la desinfeccion de lentes de contacto.
ATE516016T1 (de) Selbstemulgierende formulierungen von cetp- hemmern
BR0107716A (pt) Microemulsão herbicida
IL111625A0 (en) Phosphoric esters for use as crystallisation inhibitors
EP0497001A3 (en) Oxidized-type glutathione alkyl ester
EP0349153A3 (en) Stabilizing system for liquid hydrogen peroxide compositions and compositions so stabilized
DK1327453T3 (da) Stabile taurolidinelektrolytoplösninger
BR0009214A (pt) Composições aquosas estáveis contendo umcomposto de silìcio
SI1248600T1 (sl) Izboljšane farmacevtske formulacije inhibitorjev proteaze HIV
EP1272655A4 (en) STABILIZATION OF HIGHLY SENSITIVE NUCLEIC ACID COLORS IN AQUEOUS SOLUTION
NO20013499D0 (no) Farmasöytisk blanding omfattende en kombinasjon av en profen og andre aktive forbindelser

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: SANTEN PHARMACEUTICAL CO LTD, JP

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: SANTEN PHARMACEUTICAL CO LTD, JP

MK1K Patent expired